Regeneron

Regeneron Pharmaceuticals is a leading biotechnology company that invents, develops, and commercializes life-transforming medicines, including EYLEA and EYLEA HD for ophthalmology, Dupixent in immunology (co-developed with Sanofi), Libtayo and Lynozyfic in oncology and hematology, and Praluent for cardiovascular disease. Regeneron does not publish a public developer API; its Regeneron Genetics Center collaborates on large-scale genomic research via the UK Biobank, DiscovEHR, and partner platforms rather than a self-hosted API.

Regeneron is profiled on the APIs.io network. Tagged areas include Pharmaceutical, Biotechnology, Healthcare, and Genomics.

🌐 Visit website 📡 Source on GitHub

10.2/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs 6 Features 3 Use Cases

PharmaceuticalBiotechnologyHealthcareGenomics

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 10.2/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 0.0 / 20

Commercial Clarity 0.0 / 20

Operational Transparency 0.7 / 13

Governance 1.6 / 12

Discoverability 5.5 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/regeneron: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Features 6

Notable capabilities this provider offers.

Ophthalmology

EYLEA and EYLEA HD anti-VEGF therapies for retinal diseases

Immunology

Dupixent for atopic dermatitis, asthma, and other IL-4/IL-13 indications

Oncology and Hematology

Libtayo, Lynozyfic, and pipeline programs in oncology

Rare Diseases

Evkeeza, Veopoz, and other rare-disease therapies

Infectious Disease

Inmazeb antibody cocktail for Ebola

Genetics Research

Regeneron Genetics Center sequencing collaborations including UK Biobank

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Regeneron Domain Security

TLSv1.3 · HSTS · DMARC

SECURITY

Use Cases 3

What developers build with this provider.

Clinical Trial Discovery

Patients and HCPs locate Regeneron-sponsored trials

Drug Information

HCPs access prescribing information for Regeneron medicines

Genomic Discovery

Researchers partner with the Regeneron Genetics Center on large-cohort sequencing

Resources

Get Started 1

Portal, sign-up, and the first successful call

ClinicalTrials

ClinicalTrials

Design & Contract 1

Pagination, idempotency, versioning, errors, and events

Vocabulary

Vocabulary

Build 1

SDKs, sample code, and the tooling you integrate with

GitHubOrganization

GitHubOrganization

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Company 4

The organization behind the API

LinkedIn

Website

Website

InvestorRelations

InvestorRelations

Careers

Careers

Other 1

Properties that don't map to a standard resource type

GeneticsCenter

GeneticsCenter

Source (apis.yml)

aid: regeneron
url: https://raw.githubusercontent.com/api-evangelist/regeneron/refs/heads/main/apis.yml
name: Regeneron
type: Index
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/regeneron.png
tags:
- Pharmaceutical
- Biotechnology
- Healthcare
- Genomics
description: Regeneron Pharmaceuticals is a leading biotechnology company that invents, develops, and commercializes life-transforming
  medicines, including EYLEA and EYLEA HD for ophthalmology, Dupixent in immunology (co-developed with Sanofi), Libtayo and
  Lynozyfic in oncology and hematology, and Praluent for cardiovascular disease. Regeneron does not publish a public developer
  API; its Regeneron Genetics Center collaborates on large-scale genomic research via the UK Biobank, DiscovEHR, and partner
  platforms rather than a self-hosted API.
created: '2026-05-05'
modified: '2026-05-16'
specificationVersion: '0.19'
apis: []
common:
- type: DomainSecurity
  url: security/regeneron-domain-security.yml
- type: GitHubOrganization
  url: https://github.com/regeneron-mpds
- type: LinkedIn
  url: https://www.linkedin.com/company/regeneron-pharmaceuticals
- type: Website
  url: https://www.regeneron.com/
- type: InvestorRelations
  url: https://investor.regeneron.com/
- type: ClinicalTrials
  url: https://clinicaltrials.regeneron.com/
- type: Careers
  url: https://careers.regeneron.com/
- type: GeneticsCenter
  url: https://www.regeneron.com/science/regeneron-genetics-center
- type: Vocabulary
  url: vocabulary/regeneron-vocabulary.yml
- type: Features
  data:
  - name: Ophthalmology
    description: EYLEA and EYLEA HD anti-VEGF therapies for retinal diseases
  - name: Immunology
    description: Dupixent for atopic dermatitis, asthma, and other IL-4/IL-13 indications
  - name: Oncology and Hematology
    description: Libtayo, Lynozyfic, and pipeline programs in oncology
  - name: Rare Diseases
    description: Evkeeza, Veopoz, and other rare-disease therapies
  - name: Infectious Disease
    description: Inmazeb antibody cocktail for Ebola
  - name: Genetics Research
    description: Regeneron Genetics Center sequencing collaborations including UK Biobank
- type: UseCases
  data:
  - name: Clinical Trial Discovery
    description: Patients and HCPs locate Regeneron-sponsored trials
  - name: Drug Information
    description: HCPs access prescribing information for Regeneron medicines
  - name: Genomic Discovery
    description: Researchers partner with the Regeneron Genetics Center on large-cohort sequencing
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com